Syros Pharmaceuticals Inc (NAS:SYRS)
$ 0.2159 0.013 (6.41%) Market Cap: 5.79 Mil Enterprise Value: 7.39 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 25/100

Syros Pharmaceuticals Inc at JMP Securities Life Sciences Conference Transcript

Jun 15, 2022 / 01:30PM GMT
Release Date Price: $10.7 (+11.44%)
Jason Butler
JMP Securities LLC - Analyst

Let me say again, thank you, everybody, for being here in person at the JMP Securities 2022 life sciences conference. Next company we have with us is Syros Pharmaceuticals. We have Nancy Simonian, company's CEO. Nancy, welcome.

Nancy Simonian
Syros Pharmaceuticals, Inc. - President & CEO

Thank you.

Jason Butler
JMP Securities LLC - Analyst

So again, another busy year for you. So maybe I'd just offer it to you to give a quick high-level intro of Syros, your lead programs, and we'll jump in from there.

Nancy Simonian
Syros Pharmaceuticals, Inc. - President & CEO

Yeah. It's an incredibly exciting time at the company. We have three programs in clinical development. Our most advanced, tamibarotene, is at a Phase 3 registration-enabling study in high-risk MDS. We expect data from that study end of 2023, early 2024. We also have tamibarotene being studied in AML, and we will have data later this year from a safety lead-in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot